Compare Repligen Corporation Common Stock (RGEN) vs TTM Technologies Inc. Common Stock (TTMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TTM Technologies Inc. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while TTM Technologies Inc. Common Stock trades at $100.03 (market cap $12.22B). The key difference: Repligen Corporation Common Stock and TTM Technologies Inc. Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, TTM Technologies Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TTM Technologies Inc. Common Stock for 2 Days on average.
| RGEN | TTMI | |
|---|---|---|
Market Cap | $11.14B | $12.22B |
Volume | 1,259,263 | 3,732,329 |
Sector | Health | Technology |
52-Week High | $194.57 | $221.47 |
52-Week Low | $102.87 | $55.69 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.02B | $12.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TTMI trades at $116.10, up 5.23% today, but faces a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong revenue growth is projected, from $2.9B in 2025 to $3.4B in 2026, alongside a rising net profit margin. A significant $1.7B defense backlog and expansion in AI data-center demand support the growth narrative, though the stock's valuation multiples appear elevated.
The outlook is mixed; robust fundamentals and overwhelming analyst buy ratings (85.7%) suggest long-term potential, with a consensus price target of $203.67 implying substantial upside. However, near-term technical weakness and high valuation ratios relative to profitability metrics present risks, requiring careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TTM Technologies Inc. Common Stock
TTM Technologies manufactures printed circuit boards, radio-frequency components, and electronics assemblies. Its products are used in aerospace, defense, automotive, data center, and communications equipment.
Read more on TTMI →
